TRT Myths vs. the Research: What the Evidence Actually Shows

TRT myths vs. the research is a persistent gap: public perception of testosterone therapy still runs on outdated fears from over a decade ago, while marketing from some clinics overcorrects into overselling it as a risk-free fix for aging. Neither position reflects what the published clinical evidence actually shows. This article walks through the claims that come up most often and checks them against the research directly.

Myth: TRT causes prostate cancer

This is arguably the oldest and most persistent fear associated with testosterone therapy, and it traces back to research from the 1940s on castration slowing the progression of already-diagnosed, advanced prostate cancer — a very different clinical scenario from giving testosterone to a man without prostate cancer to treat a documented deficiency.

The modern evidence doesn't support the fear. A large Veterans Affairs cohort study followed 147,593 men with diagnosed low testosterone, comparing 58,617 who received testosterone therapy against those who didn't, and found virtually identical rates of aggressive prostate cancer between the two groups — 0.58 cases per 1,000 person-years in the treated group versus 0.57 in the untreated group (Walsh et al., PLOS ONE). Current AUA guidance reflects this: there is no convincing evidence that testosterone therapy causes prostate cancer to develop in men who don't already have it (AUA). That said, prostate health is still part of what a physician monitors during treatment — the absence of a causal link doesn't mean prostate-related labs and exams stop mattering once therapy starts.

Myth: TRT is an automatic heart attack risk

In 2015, the FDA required a boxed warning on testosterone products cautioning about cardiovascular risk, based on early observational studies and advisory panel input (FDA). That warning shaped public perception for the better part of a decade.

The question was later tested directly in the TRAVERSE trial — a large, randomized, placebo-controlled study specifically designed to evaluate cardiovascular outcomes in men with hypogonadism and existing or elevated cardiovascular risk. The result: testosterone therapy was noninferior to placebo for major adverse cardiac events, with near-identical event rates between groups (Lincoff et al., NEJM). Based substantially on that trial, the FDA removed the cardiovascular boxed warning in 2025. The accurate takeaway isn't "TRT is proven safe for every heart," though — the same trial also flagged a higher rate of non-fatal arrhythmias and blood clots in the testosterone group, and added a new warning about blood pressure increases. The myth to retire is "TRT reliably causes heart attacks." The nuance that should replace it is "cardiovascular status is still something a physician needs to evaluate and monitor," which is a very different statement.

Myth: TRT has no effect on fertility

This one runs in the opposite direction from the fear-based myths above — it's an underestimated risk, not an overestimated one. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal signaling that drives the body's own testosterone and sperm production. The research describes this plainly: exogenous testosterone is a well-documented, preventable cause of reduced fertility in men, and clinicians are specifically trained to counsel patients on this before starting treatment (Crosnoe et al.). Anyone considering future fertility needs to raise it with their physician before starting TRT, not discover the effect after the fact. More on the underlying mechanism is in how TRT works.

Myth: a single low lab result means you need TRT

Testosterone fluctuates by time of day, sleep quality, illness, and even the specific assay a lab uses. That's exactly why guideline-based diagnosis requires two separate morning readings, not one — a single number, however low it looks, isn't considered diagnostic evidence on its own under either major U.S. guideline. Treating a single test result as a green light — in either direction — isn't how legitimate diagnosis works.

Myth: more testosterone is automatically better

TRT is designed to restore a deficient level to a normal physiological range, not to push levels above what's typical for a healthy man. Pursuing higher-than-necessary levels isn't a more effective version of the same treatment — it's a different risk profile entirely, and it's part of why ongoing lab monitoring, not a fixed target chased indefinitely, is the actual standard of care.

Myth: "natural" alternatives work just as well for a real deficiency

Lifestyle factors — sleep, body composition, alcohol intake — genuinely influence testosterone levels, and addressing them is worthwhile regardless of whether someone pursues TRT. But for a man with a confirmed clinical deficiency, these factors are not interchangeable with a diagnosed medical treatment, and framing them that way can delay a legitimate diagnosis and treatment of an underlying condition that a supplement can't fix.

Myth: once your levels are "normal," estrogen and other markers don't matter anymore

A number of TRT narratives focus entirely on getting a single testosterone value into range and treat that as the finish line. The research doesn't support treating any one marker as the whole picture. Testosterone therapy interacts with at least one other hormone pathway directly — raising circulating testosterone increases the substrate available for conversion to estradiol via aromatization — and it affects red blood cell production (hematocrit) as well. A physician following the guideline-based monitoring approach is watching more than one number, on a recurring basis, not chasing a single testosterone value and calling the job done. For the full picture of the estrogen side of this specifically, see estrogen management on TRT.

Why this gap between myth and evidence matters

Both directions of misinformation cause real harm: fear keeps some men who could benefit from treatment away from a legitimate medical conversation, while overselling pushes others toward providers who skip the diagnostic rigor that actually keeps this treatment safe. The corrective in both cases is the same — evaluate claims against the published research, and route the actual treatment decision through a physician who does the same. For help evaluating whether a specific provider is practicing that way, see finding a TRT-literate physician.